CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the expansion of its Scientific Advisory Board to a combined Scientific and Medical Advisory Board as the company advances toward clinical trials in ovarian cancer and autoimmune disease. This evolution marks a significant milestone in Ernexa's transition from research to clinical-stage development. This come ...

Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiatives CAMBRIDGE, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that the Company completed the second closing under the previously announced securities purchase agreement (the "SPA") entered into on March 31, 2025 with certain accredited investors. The ...

CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the “Common Stock”), at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company’s Common Stock is expected to begin trading on a split-adjusted basis when the market opens on Ju ...

Core Insights - Ernexa Therapeutics has developed a novel iMSC-based immunotherapy platform that successfully converts "cold" ovarian tumors into "hot" tumors, potentially enhancing immune response and improving patient outcomes [1][2][4] Company Overview - Ernexa Therapeutics (Nasdaq: ERNA) focuses on innovative cell therapies for advanced cancer and autoimmune diseases, utilizing induced pluripotent stem cells (iPSCs) to create induced mesenchymal stem cells (iMSCs) [5][6] - The company is currently developing two preclinical cell therapy products: ERNA-101, aimed at activating the immune system against cancer, and ERNA-102, targeting inflammation in autoimmune diseases [6] Research Findings - The study demonstrated that iMSCs engineered to secrete cytokines IL-7 and IL-15 can migrate into the tumor microenvironment, leading to significant immune activation, including T cell and macrophage infiltration [2][3] - In a syngeneic ovarian cancer mouse model, treatment with IL-7/IL-15-secreting iMSCs resulted in a significant reduction in tumor burden and extended survival [3] Upcoming Presentation - Ernexa will present its findings at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025, with a poster titled "Engineering iPSC-derived mesenchymal stem cells (iMSCs) to secrete IL-7/IL-15 for modulation of the tumor microenvironment in a 'cold' ovarian tumor model" [4]

New entity, ErnexaTX2, reflects progress toward clinical readinessCAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly owned subsidiary based in Texas. The new entity has been established to support ongoing preclinical development of the company’s lead program, ERNA-101 for ovarian cancer, and to lay the operational groundwor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from _________ to _____________ Commission file number: 001-11460 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Ernexa Therapeutics Inc. (Exact name of registrant as specified in its charter) 1035 Cambridge St ...

CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, presented noteworthy new data at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago on April 28. The study showed how engineered cells derived from stem cells could transform the treatment of ovarian cancer. The data revealed that these engineered cells, which release powerful immune-boosting ...

Comes on the heels of company’s rebranding and new strategic direction, advancing its lead program in ovarian cancerCAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has entered into a securities purchase agreement with accredited investors for the private placement of approximately 69.3 million shares of common stock (or pre-funded warrants to purc ...

Ernexa Therapeutics embarks on new strategic direction, shifting the company's focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company's unwavering commitment to patient impact,"Breaking Through Defenses, Delivering Hope" CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics, a leader in cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the company's new name: Ernexa TherapeuticsSM (NA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 1-11460 Eterna Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 31-1103425 (State or O ...